Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:28
12/15/20
12/15
12:28
12/15/20
12:28
LLY

Eli Lilly

$163.95 /

+5.99 (+3.79%)

, PRVL

Prevail Therapeutics

$22.84 /

+10.38 (+83.31%)

, MRNA

Moderna

$148.79 /

-6.32 (-4.07%)

, WFC

Wells Fargo

$29.27 /

+0.63 (+2.20%)

, AAPL

Apple

$126.04 /

+4.25 (+3.49%)

, OCX

OncoCyte

$2.83 /

+0.71 (+33.49%)

, BNR

Burning Rock Biotech

$23.85 /

-0.95 (-3.83%)

, ARVN

Arvinas

$68.50 /

+10.16 (+17.42%)

, MIRM

Mirum Pharmaceuticals

$19.01 /

-5.12 (-21.22%)

, MESO

Mesoblast

$13.60 /

-3.25 (-19.29%)

The major averages are…

ShowHide Related Items >><<
WFC Wells Fargo
$29.27 /

+0.63 (+2.20%)

PRVL Prevail Therapeutics
$22.84 /

+10.38 (+83.31%)

OCX OncoCyte
$2.83 /

+0.71 (+33.49%)

MRNA Moderna
$148.79 /

-6.32 (-4.07%)

MIRM Mirum Pharmaceuticals
$19.01 /

-5.12 (-21.22%)

MESO Mesoblast
$13.60 /

-3.25 (-19.29%)

LLY Eli Lilly
$163.95 /

+5.99 (+3.79%)

BNR Burning Rock Biotech
$23.85 /

-0.95 (-3.83%)

ARVN Arvinas
$68.50 /

+10.16 (+17.42%)

AAPL Apple
$126.04 /

+4.25 (+3.49%)

LLY Eli Lilly
$163.95 /

+5.99 (+3.79%)

12/15/20 Piper Sandler
Prevail Therapeutics downgraded to Neutral from Overweight at Piper Sandler
12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/04/20 JPMorgan
Eli Lilly best positioned growth story in space, says JPMorgan
PRVL Prevail Therapeutics
$22.84 /

+10.38 (+83.31%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
MRNA Moderna
$148.79 /

-6.32 (-4.07%)

12/14/20 Jefferies
Novavax initiated with a Buy at Jefferies
12/14/20 Citi
Arcturus Therapeutics price target raised to $133 from $62 at Citi
12/09/20
Fly Intel: Top five analyst downgrades
12/09/20 Needham
Moderna downgraded to Hold at Needham after 770% year-to-date run
WFC Wells Fargo
$29.27 /

+0.63 (+2.20%)

12/14/20 Keefe Bruyette
Universal Banks upgraded to Overweight from Market Weight at Keefe Bruyette
12/14/20 Keefe Bruyette
Wells Fargo upgraded to Outperform from Market Perform at Keefe Bruyette
12/11/20 Credit Suisse
Wells Fargo price target raised to $35 from $33 at Credit Suisse
11/30/20 Morgan Stanley
Morgan Stanley upgrades Large Cap Banks & Consumer Finance to Attractive
AAPL Apple
$126.04 /

+4.25 (+3.49%)

12/15/20 JPMorgan
JPMorgan sees 20% upside for Apple shares in 2021
12/11/20 Citi
Citi would look to add to Qualcomm positions, calls Apple report 'no biggie'
12/11/20 Raymond James
Apple modem report sinking Qualcomm doesn't offer new info, says Raymond James
12/11/20 Canaccord
Qualcomm pullback on Apple modem report a buying opportunity, says Canaccord
OCX OncoCyte
$2.83 /

+0.71 (+33.49%)

11/30/20 BTIG
OncoCyte initiated with a Buy at BTIG
11/13/20 Piper Sandler
OncoCyte price target raised to $2 from $1.50 at Piper Sandler
11/09/20 KeyBanc
OncoCyte initiated with an Overweight at KeyBanc
07/01/20
Fly Intel: Top five analyst downgrades
BNR Burning Rock Biotech
$23.85 /

-0.95 (-3.83%)

07/07/20 Cowen
Burning Rock Biotech initiated with an Outperform at Cowen
07/07/20 Morgan Stanley
Burning Rock Biotech initiated with an Overweight at Morgan Stanley
07/07/20 Cowen
Burning Rock Biotech initiated with an Outperform at Cowen
ARVN Arvinas
$68.50 /

+10.16 (+17.42%)

12/15/20 Roth Capital
Arvinas price target raised to $120 from $65 at Roth Capital
12/15/20 Citi
Arvinas price target raised to $123 from $43 at Citi
12/14/20 Oppenheimer
Oppenheimer upgrades Arvinas to Outperform after encouraging clinical updates
12/14/20 Oppenheimer
Arvinas upgraded to Outperform from Perform at Oppenheimer
MIRM Mirum Pharmaceuticals
$19.01 /

-5.12 (-21.22%)

12/09/20 Piper Sandler
Mirum Pharmaceuticals investor day highlights pipeline advances, says Piper
11/30/20 Piper Sandler
Mirum continues to deliver on milestones, says Piper Sandler
11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
MESO Mesoblast
$13.60 /

-3.25 (-19.29%)

12/04/20
Fly Intel: Top five analyst downgrades
12/04/20 Chardan
Mesoblast downgraded to Sell from Neutral at Chardan
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 RBC Capital
Mesoblast initiated with a Sector Perform at RBC Capital
WFC Wells Fargo
$29.27 /

+0.63 (+2.20%)

PRVL Prevail Therapeutics
$22.84 /

+10.38 (+83.31%)

OCX OncoCyte
$2.83 /

+0.71 (+33.49%)

MRNA Moderna
$148.79 /

-6.32 (-4.07%)

MIRM Mirum Pharmaceuticals
$19.01 /

-5.12 (-21.22%)

MESO Mesoblast
$13.60 /

-3.25 (-19.29%)

LLY Eli Lilly
$163.95 /

+5.99 (+3.79%)

BNR Burning Rock Biotech
$23.85 /

-0.95 (-3.83%)

ARVN Arvinas
$68.50 /

+10.16 (+17.42%)

AAPL Apple
$126.04 /

+4.25 (+3.49%)

  • 16
    Dec
  • 15
    Dec
  • 04
    Dec
  • 12
    Jun
  • 19
    May
  • 12
    Feb
  • 09
    Jan
WFC Wells Fargo
$29.27 /

+0.63 (+2.20%)

MRNA Moderna
$148.79 /

-6.32 (-4.07%)

LLY Eli Lilly
$163.95 /

+5.99 (+3.79%)

AAPL Apple
$126.04 /

+4.25 (+3.49%)

WFC Wells Fargo
$29.27 /

+0.63 (+2.20%)

PRVL Prevail Therapeutics
$22.84 /

+10.38 (+83.31%)

OCX OncoCyte
$2.83 /

+0.71 (+33.49%)

MRNA Moderna
$148.79 /

-6.32 (-4.07%)

MIRM Mirum Pharmaceuticals
$19.01 /

-5.12 (-21.22%)

MESO Mesoblast
$13.60 /

-3.25 (-19.29%)

LLY Eli Lilly
$163.95 /

+5.99 (+3.79%)

ARVN Arvinas
$68.50 /

+10.16 (+17.42%)

AAPL Apple
$126.04 /

+4.25 (+3.49%)

WFC Wells Fargo
$29.27 /

+0.63 (+2.20%)

MRNA Moderna
$148.79 /

-6.32 (-4.07%)

MESO Mesoblast
$13.60 /

-3.25 (-19.29%)

LLY Eli Lilly
$163.95 /

+5.99 (+3.79%)

AAPL Apple
$126.04 /

+4.25 (+3.49%)

On The Fly
Fly Intel: Pre-market Movers » 08:59
12/15/20
12/15
08:59
12/15/20
08:59
PRVL

Prevail Therapeutics

$12.50 /

+0.81 (+6.93%)

, LLY

Eli Lilly

$157.96 /

-2.08 (-1.30%)

, MRNA

Moderna

$155.02 /

-1.75 (-1.12%)

, OCX

OncoCyte

$2.12 /

-0.1 (-4.50%)

, AVXL

Anavex

$5.20 /

+0.185 (+3.69%)

, ATNX

Athenex

$12.29 /

+0.74 (+6.41%)

, MIRM

Mirum Pharmaceuticals

$24.19 /

-1.54 (-5.99%)

, MESO

Mesoblast

$16.85 /

-0.21 (-1.23%)

, EAF

GrafTech

$9.65 /

-0.14 (-1.43%)

, OCUL

Ocular Therapeutix

$22.31 /

+1.57 (+7.57%)

Check out this morning's…

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$12.50 /

+0.81 (+6.93%)

OCX OncoCyte
$2.12 /

-0.1 (-4.50%)

OCUL Ocular Therapeutix
$22.31 /

+1.57 (+7.57%)

MRNA Moderna
$155.02 /

-1.75 (-1.12%)

MIRM Mirum Pharmaceuticals
$24.19 /

-1.54 (-5.99%)

MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

LLY Eli Lilly
$157.96 /

-2.08 (-1.30%)

EAF GrafTech
$9.65 /

-0.14 (-1.43%)

AVXL Anavex
$5.20 /

+0.185 (+3.69%)

ATNX Athenex
$12.29 /

+0.74 (+6.41%)

PRVL Prevail Therapeutics
$12.50 /

+0.81 (+6.93%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
LLY Eli Lilly
$157.96 /

-2.08 (-1.30%)

12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/10/20 Wolfe Research
Eli Lilly upgraded to Outperform from Peer Perform at Wolfe Research
12/04/20 JPMorgan
Eli Lilly best positioned growth story in space, says JPMorgan
12/02/20 Stifel
Blueprint Medicines initiated with a Hold at Stifel
MRNA Moderna
$155.02 /

-1.75 (-1.12%)

12/14/20 Jefferies
Novavax initiated with a Buy at Jefferies
12/14/20 Citi
Arcturus Therapeutics price target raised to $133 from $62 at Citi
12/09/20
Fly Intel: Top five analyst downgrades
12/09/20 Needham
Moderna downgraded to Hold at Needham after 770% year-to-date run
OCX OncoCyte
$2.12 /

-0.1 (-4.50%)

11/30/20 BTIG
OncoCyte initiated with a Buy at BTIG
11/13/20 Piper Sandler
OncoCyte price target raised to $2 from $1.50 at Piper Sandler
11/09/20 KeyBanc
OncoCyte initiated with an Overweight at KeyBanc
07/01/20
Fly Intel: Top five analyst downgrades
AVXL Anavex
$5.20 /

+0.185 (+3.69%)

10/21/20 H.C. Wainwright
Anavex price target raised to $14 from $12 at H.C. Wainwright
09/28/20 Ladenburg
Ladenburg starts Anavex with Buy rating, $12 price target
09/28/20 Ladenburg
Anavex initiated with a Buy at Ladenburg
03/16/20
Fly Intel: Top five analyst initiations
ATNX Athenex
$12.29 /

+0.74 (+6.41%)

10/26/20
Fly Intel: Top five analyst initiations
10/26/20 SVB Leerink
Athenex initiated with an Outperform at SVB Leerink
09/01/20 RBC Capital
Athenex price target raised to $33 from $31 at RBC Capital
MIRM Mirum Pharmaceuticals
$24.19 /

-1.54 (-5.99%)

12/09/20 Piper Sandler
Mirum Pharmaceuticals investor day highlights pipeline advances, says Piper
11/30/20 Piper Sandler
Mirum continues to deliver on milestones, says Piper Sandler
11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

12/04/20
Fly Intel: Top five analyst downgrades
12/04/20 Chardan
Mesoblast downgraded to Sell from Neutral at Chardan
10/22/20
Fly Intel: Top five analyst initiations
10/22/20 RBC Capital
Mesoblast initiated with a Sector Perform at RBC Capital
EAF GrafTech
$9.65 /

-0.14 (-1.43%)

02/13/20 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
02/13/20 RBC Capital
GrafTech downgraded to Sector Perform from Outperform at RBC Capital
12/17/19 BMO Capital
GrafTech downgraded to Market Perform from Outperform at BMO Capital
OCUL Ocular Therapeutix
$22.31 /

+1.57 (+7.57%)

11/13/20 Raymond James
Ocular Therapeutix price target raised to $25 from $15 at Raymond James
11/11/20 Piper Sandler
Piper says Ocular data 'very much supportive' of plans to advance OTX-TKI
11/06/20 H.C. Wainwright
Ocular Therapeutix price target raised to $14 from $13 at H.C. Wainwright
11/05/20 Piper Sandler
Ocular Therapeutix price target raised to $16 from $14 at Piper Sandler
PRVL Prevail Therapeutics
$12.50 /

+0.81 (+6.93%)

OCX OncoCyte
$2.12 /

-0.1 (-4.50%)

OCUL Ocular Therapeutix
$22.31 /

+1.57 (+7.57%)

MRNA Moderna
$155.02 /

-1.75 (-1.12%)

MIRM Mirum Pharmaceuticals
$24.19 /

-1.54 (-5.99%)

MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

LLY Eli Lilly
$157.96 /

-2.08 (-1.30%)

EAF GrafTech
$9.65 /

-0.14 (-1.43%)

AVXL Anavex
$5.20 /

+0.185 (+3.69%)

ATNX Athenex
$12.29 /

+0.74 (+6.41%)

  • 15
    Dec
  • 16
    Dec
  • 15
    Dec
  • 14
    Oct
  • 10
    Sep
  • 20
    May
  • 19
    May
  • 12
    Feb
  • 09
    Jan
MRNA Moderna
$155.02 /

-1.75 (-1.12%)

LLY Eli Lilly
$157.96 /

-2.08 (-1.30%)

PRVL Prevail Therapeutics
$12.50 /

+0.81 (+6.93%)

OCX OncoCyte
$2.12 /

-0.1 (-4.50%)

OCUL Ocular Therapeutix
$22.31 /

+1.57 (+7.57%)

MRNA Moderna
$155.02 /

-1.75 (-1.12%)

MIRM Mirum Pharmaceuticals
$24.19 /

-1.54 (-5.99%)

MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

LLY Eli Lilly
$157.96 /

-2.08 (-1.30%)

AVXL Anavex
$5.20 /

+0.185 (+3.69%)

ATNX Athenex
$12.29 /

+0.74 (+6.41%)

MRNA Moderna
$155.02 /

-1.75 (-1.12%)

MESO Mesoblast
$16.85 /

-0.21 (-1.23%)

LLY Eli Lilly
$157.96 /

-2.08 (-1.30%)

Syndicate
Mirum Pharmaceuticals 3.75M share Secondary priced at $20.00 » 21:02
12/14/20
12/14
21:02
12/14/20
21:02
MIRM

Mirum Pharmaceuticals

$24.19 /

-1.54 (-5.99%)

The deal priced below the…

The deal priced below the last closing price of $24.00. JMP Securities, SVB Leerink and Evercore ISI are acting as joint book running managers for the offering.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$24.19 /

-1.54 (-5.99%)

MIRM Mirum Pharmaceuticals
$24.19 /

-1.54 (-5.99%)

12/09/20 Piper Sandler
Mirum Pharmaceuticals investor day highlights pipeline advances, says Piper
11/30/20 Piper Sandler
Mirum continues to deliver on milestones, says Piper Sandler
11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
MIRM Mirum Pharmaceuticals
$24.19 /

-1.54 (-5.99%)

  • 15
    Dec
  • 09
    Jan
MIRM Mirum Pharmaceuticals
$24.19 /

-1.54 (-5.99%)

Syndicate
Mirum Pharmaceuticals files to sell $75M of common stock » 07:48
12/14/20
12/14
07:48
12/14/20
07:48
MIRM

Mirum Pharmaceuticals

$25.73 /

+0.81 (+3.25%)

J.P. Morgan, SVB Leerink…

J.P. Morgan, SVB Leerink and Evercore ISI are acting as joint book-running managers for the proposed offering. H.C. Wainwright & Co. is acting as lead manager for the proposed offering.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$25.73 /

+0.81 (+3.25%)

MIRM Mirum Pharmaceuticals
$25.73 /

+0.81 (+3.25%)

12/09/20 Piper Sandler
Mirum Pharmaceuticals investor day highlights pipeline advances, says Piper
11/30/20 Piper Sandler
Mirum continues to deliver on milestones, says Piper Sandler
11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
MIRM Mirum Pharmaceuticals
$25.73 /

+0.81 (+3.25%)

  • 09
    Jan
MIRM Mirum Pharmaceuticals
$25.73 /

+0.81 (+3.25%)

Recommendations
Mirum Pharmaceuticals investor day highlights pipeline advances, says Piper » 20:58
12/09/20
12/09
20:58
12/09/20
20:58
MIRM

Mirum Pharmaceuticals

$24.18 /

+0.5 (+2.11%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi keeps an Overweight rating and $77 price target on Mirum Pharmaceuticals after its investor day presentation highlighted the company's pipeline advancements with two ASBT inhibitors. The analyst says the company is embarking on "the largest market pediatric cholestatic opportunity in biliary atresia", adding that she walked away "very impressed by the thoughtful design of the randomized, double-blind, placebo-controlled Phase 2 study of 600mg/kg dose of Maralixibat called EMBARK.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$24.18 /

+0.5 (+2.11%)

MIRM Mirum Pharmaceuticals
$24.18 /

+0.5 (+2.11%)

11/30/20 Piper Sandler
Mirum continues to deliver on milestones, says Piper Sandler
11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
MIRM Mirum Pharmaceuticals
$24.18 /

+0.5 (+2.11%)

  • 09
    Jan
MIRM Mirum Pharmaceuticals
$24.18 /

+0.5 (+2.11%)

Hot Stocks
Mirum Pharmaceuticals, Oberland announce up to $210M funding arrangement » 09:11
12/09/20
12/09
09:11
12/09/20
09:11
MIRM

Mirum Pharmaceuticals

$23.64 /

+0.13 (+0.55%)

Mirum Pharmaceuticals and…

Mirum Pharmaceuticals and Oberland Capital announced a $200M capped, tiered, revenue-based funding agreement based on net revenues of maralixibat, as well as a $10M equity investment agreement. Under the agreements, Mirum will receive: $60M by December 31, including a $10M equity investment; $65M upon announcement of the FDA acceptance of Mirum's new drug application, or NDA, for maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome, or ALGS; $35M upon announcement of FDA approval of maralixibat for cholestatic pruritus in patients with ALGS and $50M, at the option of Oberland Capital, which may be funded to support in-licensing or acquisition of assets to further build upon Mirum's development and commercialization pipeline in the pursuit of treatments for rare liver diseases. Mirum is submitting a rolling NDA to the FDA for maralixibat for the treatment of cholestatic pruritus in patients with ALGS, which it expects to complete in the first quarter of 2021, with launch planned in the second half of 2021. Mirum has also submitted a marketing authorization application (MAA) to the European Medicines Agency, or EMA, for maralixibat for the treatment of patients with progressive familial intrahepatic cholestasis type 2, or PFIC2, or bile salt export pump, or BSEP, deficiency. The MAA was recently validated by the EMA and Mirum is preparing for launch in the European Union in the first quarter of 2022.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$23.64 /

+0.13 (+0.55%)

MIRM Mirum Pharmaceuticals
$23.64 /

+0.13 (+0.55%)

11/30/20 Piper Sandler
Mirum continues to deliver on milestones, says Piper Sandler
11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
09/28/20 Piper Sandler
Mirum opportunity in Alagille syndrome higher than expected, says Piper Sandler
MIRM Mirum Pharmaceuticals
$23.64 /

+0.13 (+0.55%)

  • 09
    Jan
MIRM Mirum Pharmaceuticals
$23.64 /

+0.13 (+0.55%)

Conference/Events
Mirum Pharmaceuticals to host virtual investor day » 18:13
12/04/20
12/04
18:13
12/04/20
18:13
MIRM

Mirum Pharmaceuticals

$23.90 /

+0.04 (+0.17%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 9 at 11 am. Webcast Link

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$23.90 /

+0.04 (+0.17%)

MIRM Mirum Pharmaceuticals
$23.90 /

+0.04 (+0.17%)

11/30/20 Piper Sandler
Mirum continues to deliver on milestones, says Piper Sandler
11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
09/28/20 Piper Sandler
Mirum opportunity in Alagille syndrome higher than expected, says Piper Sandler
MIRM Mirum Pharmaceuticals
$23.90 /

+0.04 (+0.17%)

  • 09
    Jan
MIRM Mirum Pharmaceuticals
$23.90 /

+0.04 (+0.17%)

Recommendations
Mirum continues to deliver on milestones, says Piper Sandler » 10:36
11/30/20
11/30
10:36
11/30/20
10:36
MIRM

Mirum Pharmaceuticals

$23.50 /

+1.38 (+6.24%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi says Mirum Pharmaceuticals "continues to deliver milestones on time and achieve every goal it sets," with this morning's announcement of Marketing Authorization Application validation for maralixibat in PFIC2. The application validation has a "strong basis" in Mirum's five-year dataset showing transplant-free survival in PFIC2 patients on maralixibat, Rahimi tells investors in a research note. The analyst looks forward to Mirum's investor day on December 9 and keeps an Overweight rating on the shares with a $77 price target.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$23.50 /

+1.38 (+6.24%)

MIRM Mirum Pharmaceuticals
$23.50 /

+1.38 (+6.24%)

11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
09/28/20 Piper Sandler
Mirum opportunity in Alagille syndrome higher than expected, says Piper Sandler
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
MIRM Mirum Pharmaceuticals
$23.50 /

+1.38 (+6.24%)

  • 09
    Jan
MIRM Mirum Pharmaceuticals
$23.50 /

+1.38 (+6.24%)

Hot Stocks
Mirum Pharmaceuticals announces maralixibat MAA accepted for review by EMA » 08:40
11/30/20
11/30
08:40
11/30/20
08:40
MIRM

Mirum Pharmaceuticals

$22.06 /

+0.38 (+1.75%)

Mirum Pharmaceuticals…

Mirum Pharmaceuticals announced that the company's marketing authorization application, or MAA, for its investigational medicine, maralixibat, for the treatment of patients with progressive familial intrahepatic cholestasis type 2, or PFIC2, also known as bile salt export pump, or BSEP, deficiency, was accepted for review by the European Medicines Agency, or EMA. The validation of the application by the EMA confirms all essential regulatory elements are included in the submission such that the EMA can begin its review.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$22.06 /

+0.38 (+1.75%)

MIRM Mirum Pharmaceuticals
$22.06 /

+0.38 (+1.75%)

11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
09/28/20 Piper Sandler
Mirum opportunity in Alagille syndrome higher than expected, says Piper Sandler
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
MIRM Mirum Pharmaceuticals
$22.06 /

+0.38 (+1.75%)

  • 09
    Jan
MIRM Mirum Pharmaceuticals
$22.06 /

+0.38 (+1.75%)

Hot Stocks
Mirum Pharmaceuticals announces data from ITCH, IMAGINE II studies » 18:32
11/15/20
11/15
18:32
11/15/20
18:32
MIRM

Mirum Pharmaceuticals

$19.26 /

+1.18 (+6.53%)

Mirum Pharmaceuticals…

Mirum Pharmaceuticals announced data presented at the Annual Meeting of the American Association for the Study of Liver Diseases - The Liver Meeting Digital Experience. The data were presented in a late-breaking oral presentation titled "Preliminary Analysis of ITCH and IMAGINE II - Outcome of Long-term Administration of Maralixibat in Children with Alagille Syndrome." The objective of the studies was to assess pruritus and other markers of cholestasis in patients with Alagille syndrome with up to 220 weeks of treatment with maralixibat. Maralixibat, an apical sodium bile acid transporter inhibitor, has previously been shown to interrupt the enterohepatic circulation of bile acids, reducing pruritus. Of the children enrolled in the ITCH and IMAGINE II studies, 28 of the 37 patients were on study at 48 weeks with 80% of those experiencing clinically meaningful reductions in pruritus which were durable beyond four years, with 90% of patients who continued on study experiencing a pruritus response at the end of treatment. The mean reduction in ItchRO at week 48 was -1.9 points and deepened to -2.3 points at the end of treatment. Maralixibat treatment improved quality of life and led to improved growth parameters. The long-term data suggest that maralixibat has the potential to be an effective treatment and could serve as an alternative to surgery for ALGS patients, if approved.

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$19.26 /

+1.18 (+6.53%)

MIRM Mirum Pharmaceuticals
$19.26 /

+1.18 (+6.53%)

11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
09/28/20 Piper Sandler
Mirum opportunity in Alagille syndrome higher than expected, says Piper Sandler
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
MIRM Mirum Pharmaceuticals
$19.26 /

+1.18 (+6.53%)

  • 09
    Jan
MIRM Mirum Pharmaceuticals
$19.26 /

+1.18 (+6.53%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.